The
Food and Drug Administration will not require Esperion Therapeutics
Inc. (Nasdaq: ESPR) to complete a cardiovascular outcomes trial for ETC-1002
but concerns remained about the scope of further clinical trials. The stock price plunged $11.34 to close at $64.17.
Esperion does not need cardiovascular outcomes trial
August 18, 2015 at 10:22 AM EDT
